Data extraction and quality assessment were performed, focusing on primary outcomes, including changes in triglycerides (TG), total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and very low-density lipoprotein (VLDL), and secondary outcomes including blood pressure (BP) and body mass index (BMI)
Further, NOX2 depletion and the NOX inhibitor apocynin were able to reduce NF-KB activation, demonstrating how ROS can lead to the increased expression of proinflammatory cytokines (Shekh-Ahmad et al., 2019, 2018)
Wegovy 0.5 mg, FlexTouch solution for injection in pre-filled pen Summary of Product Characteristics
Compounded preparations are not reviewed or approved by the FDA for safety, effectiveness, or quality before they are marketed